Guangdong Zhongsheng Pharmaceutical Co.,Ltd.
众生药业
002317
Shenzhen Stock Exchange
Company Profile
1.To support the strong, healthy, and steady growth of the corporation performance, Zhongsheng Pharma is in possession of a line of extensive products of a rational distribution and of various ranks, which comply closely with the latest national medication policy and aim at satisfying the overall sales demand. 2.The registered varieties of Quality Consistency Evaluation for Generic Drugs will become the supporting point of the new business volumes of Zhongsheng Pharma. 3.The generic drugs, the research projects of which are being conducted orderly and efficiently, will further expand the its product library and uphold the business performances of Zhongsheng Pharma. 4.A characteristic innovative product line shall lead Zhongsheng Pharma into a brighter and better future.
Full description
Established in 1979, Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SZSE A SHARE: 002317) has grown into a bio-pharmaceutical corporation dedicated to pharmaceuticals developing, manufacturing and marketing. Aspired to be one of the top-ranking healthcare and pharmaceutical groups in China, Zhongsheng Pharma, through its robust endogenous growth along with smart merger and acquisition strategy, reinforces its sustained and stable growth in pharmaceutical manufacturing and even steps out to moderately extend its business to areas of medical service and health managements. Designated to always provide the superior products and service for the care of lives, Zhongsheng Pharma has always followed a sound path of development and has derived a wide variety of products in such major fields as ophthalmology, gastroenterology, respiratory diseases, cardiovascular and cerebrovascular diseases. Driven by its developing strategy, Zhongsheng Pharma, concerning with the prospective variations in the spectrum of human diseases, keeps a close eye on the blue ocean market and, as to fulfill the unmet clinic needs, plough into innovative medicine research for products resolving such problems as MASH, organic fibrosis, neoplasm, influenza and cardiovascular and cerebrovascular diseases. Its innovation sustains its robust growth and leads itself into a brighter and better future.